Participants who received treatment with namilumab in the previous study M1-1188-002-EM (PRIORA [NCT01317797]) will have two whole blood samples (3 mL each) collected to correlate genetic markers with namilumab treatment responses as determined in the previous study.~The study will enroll approximately 14 participants who received namilumab in the previous study.~• No intervention is administered in this study.~This trial will be conducted in Bulgaria, Spain and The Netherlands. The overall time to participate in this study is 1 day.
The purpose of this study is to obtain blood samples from up to 14 participants who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, [NCT01317797]) to correlate genetic markers with clinical outcomes.